P
PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?
Investor insights
Funding rounds participated in
$20M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Funding rounds raised
Total raised
$20M
from 1 investors over 1 rounds
P
PreludeDx raised $20M on April 22, 2022
Investors: Evidity Health Capital